High materiality8/10
UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS targets $33; posted price $17.27.
- UBS Buy target $33; price $17.27
Key facts
- 01
Target: $33
- 02
Posted price: $17.27
- 03
Analyst firm: UBS
- 04
Analyst: David Dai
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.